P2P review · GLP-1/GIP dual agonist
Tirzepatide (Mounjaro/Zepbound) P2P review prep
GLP-1/GIP dual agonist. Indications: T2DM (Mounjaro), obesity (Zepbound)
Drug class
GLP-1/GIP dual agonist
Payer criteria typically applied
- Step therapy with metformin
- Comorbidity documentation for Zepbound
Common medical director objections
- Mounjaro for obesity (use Zepbound)
- Step therapy not exhausted
Pitfalls to avoid
- Combination prior therapy required
Frequently asked questions
What does the payer typically require for Tirzepatide (Mounjaro/Zepbound)?
Step therapy with metformin; Comorbidity documentation for Zepbound.
What objections does the medical director typically raise?
Mounjaro for obesity (use Zepbound); Step therapy not exhausted.
What pitfalls should I avoid during the P2P call?
Combination prior therapy required.
Sources
Prep Tirzepatide (Mounjaro/Zepbound) P2Ps faster — try ApprovalHelp free
ApprovalHelp auto-prepares P2P talking points from the patient's chart, surfaces payer-specific objections, and generates the post-call appeal draft. no setup fee.
Get started →Contact: hello@approvalhelp.com